Popular on s4story
- Jeffrey Hartman, inspires a movement of global change for good with his new book, "Because There Was Margoth: One Good Deed Serves Another."
- Women In Professional Sports To Celebrate 10 Years of Service, Sportsmanship & Sisterhood
- Lisa Ard signs One-Book deal with Creative James Media
- Distinguished New York Trial Attorney and Author Donates Book Proceeds to NYU Cancer Research Center
- VMH Publishing Becomes Recipient of Comcast (Rise), Renowned Internet & Provider
- The Fuse Group Announces New FOLKS President Amélie Poitras
- Diedra Harrison-Greenaway launches new book titled: The Blueprint: A Guide Towards Cannabis Business Ownership
- Skin Center Enjoys Rave Reviews For Their Microneedling Service
- Escribe Publishing Mourns Death of Author, John A. Brennan
- Serenity Movers Delivers First-Class Moving Services in NYC
Similar on s4story
- Why Market Timing is a Bad Idea
- Improvement, data science pros to convene in Atlanta Sept. 19-21
- Multi #1 International Best-Selling Author Jennifer S. Wilkov Announces the 2022 October Speak Up Women Conference and Last Call For Speakers
- Contracting Resources Group, Inc. Named on Inc. 5000 List of Fastest-Growing Private Companies for Fifth Year
- Former Marine Sergeant Michael J. Rotch Launches Life Coaching Program, Helping People Find Their Voice
- Update on I-5 Project, Black Prime Contractor Raimore Construction
- Ironside Human Resources Ranks No.765 on the 2022 Inc. 5000 Annual List
- Global Workplace Mental Health Provider CuraLinc Healthcare Debuts on the Inc. 5000 List
- Arizona Fireplaces Ranks No. 3277 on the 2022 Inc. 5000 Annual List
- Loxperts Inc. launches the first-ever on-demand freelancer marketplace dedicated to localization experts
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
S For Story/10549714
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2022, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 37,250 shares of Puma common stock to six new non-executive employees.
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, August 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on S For Story
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, August 1, 2022, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
More on S For Story
- MainConcept and Fraunhofer IIS to showcase the future of video and audio with VVC and MPEG-H Audio
- New book about discovering King Tut's tomb is published
- Orbex Launches "The Ultimate Trading Course" Live Educational Series
- "DJ Mark Battle" Keeps Draymond Green on the dancefloor for hours during Wedding Weekend Extravaganza
- Why Market Timing is a Bad Idea
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Contacts
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Filed Under: Business
0 Comments
Latest on S For Story
- Bundledocs launch new Cloud PDF Editor as part of their entry into North American market
- Non-profit Responds to Post Covid Needs
- Eagan Immigration Announces Their Debut on the Inc. 5000
- The Stage is Set for The 2022 DLH Inspire Awards in Hollywood
- New! Volume 11 Quote Acrostic Favorites: Featuring 50 Rewarding Puzzles
- Contracting Resources Group, Inc. Named on Inc. 5000 List of Fastest-Growing Private Companies for Fifth Year
- Former Marine Sergeant Michael J. Rotch Launches Life Coaching Program, Helping People Find Their Voice
- Climate Justice Advocate, Felicia Davis, Statement on the Inflation Reduction Act
- Update on I-5 Project, Black Prime Contractor Raimore Construction
- The J Announces Full Author Lineup for 44th Annual St. Louis Jewish Book Festival
- Century Fasteners Corp. – Christopher Hussey, Hired
- Aquia Inc. Announces Government and Cyber Veteran Advisory Board; Names Renee Wynn Inaugural Member
- Ironside Human Resources Ranks No.765 on the 2022 Inc. 5000 Annual List
- CareWell Health Medical Center Expands Leadership Team, Adds New COO
- Global Workplace Mental Health Provider CuraLinc Healthcare Debuts on the Inc. 5000 List
- Tales of Wonder and Dread To Mark Anniversary With New Books
- Arizona Fireplaces Ranks No. 3277 on the 2022 Inc. 5000 Annual List
- Motherly Named to 2022 Inc. 5000 Annual List Among America's Fastest-Growing Private Companies
- Summit Report Released: Keeping Schools Open in 2022 and Beyond
- Bold New Book, If Only We Knew, Offers A Framework To Understand And Solve Today's Social Issues